The fact is when we look at ROSA and/or any other robotics-related initiatives that we have, these are key priorities. Yeah. Across ZB, this impact became most pronounced in mid- to late March. And since then, procedures in China have steadily increased, exiting the last week of the first quarter at about 40% down. I think that you've got such a confusing quarter given day rate differences, given mix of business in certain parts of the world that may or may not have been hit as hard as other parts of the world from the COVID-19 issue. There are other variables that make it harder to determine when they're going to come back. Net sales were just under $1.8 billion, a reported decrease of 9.7% from the prior year and an operational decrease of 8.9% excluding the impact of foreign currency changes. They're obviously a couple of months ahead of us in this whole thing, and they've got a patient backlog there too of course but utilization seems to kind of still be stuck around down 25% through April. We believe that this progress and, truthfully, our proactive stance and our financial stability also give us key competitive advantages right now during this challenging time that could open up new opportunities not just to drive innovation, but also grow our business and our share position in the near term. Thank you. A digital recording will be available after the completion of the conference call, from November 6, 2020 to January 10, 2021. And actually, having the restructuring plan and the working group in place to move it forward actually helped us to quickly pivot and aggressively cut costs as a result of the COVID-19 challenges using the very work streams and really the mindset that we had in place for this program. And there's nothing that we've seen in the short term that at all, in any way, shape or form, changes that viewpoint. Thank you. Our global knee business declined 8.3%. One, countries impacted more severely which represents more than half of the region including countries like Italy, Spain, France, the U.K. and others, where we saw a significant reduction in procedures starting in mid-March and exiting the final weeks of the quarter down about 80% versus the prior year. We're highly focused on the high-priority, high-growth areas of our business, and we're making investments to continue to drive innovation in those areas. Lastly, the Americas decreased 7.7%. Given the current environment, we will not be providing updated financial 2020 guidance. And so again, I really do think that we moved aggressively and took a very proactive stance because we had the road map already laid out through that planning process. Bitte zusätzlich den Namen des neuen Portfolios angeben. Together with healthcare professionals, we help millions of people live better lives. Free cash flow should have a similar profile to earnings. This will not deter us from continuing to double down in those key areas, and I'll talk more about that in a minute. I wouldn't hear a lot of talk about economy on this call. Most recently, many states are taking policy steps to reopen elective procedures with the vast majority expected to do so by mid-May. OK. Moving on to No. But the raising level of improvement remains fluid. Yeah. So if anything for me, when I think about 2021 and potentially even beyond, I think we could have an opportunity as a market which would be a false positive, but I think we could have a situation where you're seeing extraordinary growth during that time rather than depressed growth because of any kind of economic recovery issue. I just also want to say before I get started that I certainly hope that you and your families are healthy and safe and trying to get used to this unusual environment that we're working in and living in right now. Could you please spend a minute on what it takes to roll out mymobility, and how you plan on -- or how you expect on seeing this in action as we get back to sort of a new normal? Thanks Keri. So to be able to put a specific time frame in place is challenging. That ultimately bodes well for all of us. We're loading that through our sales force program, and we're able to use those insights to be able to give us a view of what we should expect. I'm proud of how the ZB team has responded to the crisis. Given the fact that it is so unprecedented when we think about COVID-19 and really just thinking through it, there really is no proxy that you can look back on that would give you the pathway forward as a result of looking at that historic view. And really just when the patient's going to be ready to come back in. I want to come back to China. And all the while, they've done all of this without disrupting our overall supply chain. What I would tell you is that pretty much across the board, our procedures -- most of the procedures can be done in ASC setting, where our big volume comes in. Interest expense of $51 million was down versus the prior year due to debt paydown through 2019. It's too early to determine the ramp of procedures in those states, but this is an encouraging sign. So we do expect that to be a bigger impact. You mentioned that you're still investing there, but I'm just curious how or if your commercial approach may have changed for 2020, just given the current backdrop. We ended the first quarter with cash and marketable securities of about $2.4 billion, and we generated approximately $325 million of free cash flow in the quarter. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. Thanks so much. I don't want to predict better pricing, but I also don't want to predict worse pricing in the short term here. Additionally, the discussions on this call will include certain non-GAAP financial measures. And with that, I'm going to turn the call back over to Keri to move into the Q&A portion of the call. Interestingly enough, last year, as a part of a broader risk mitigation kind of a planning process that we are going through, crisis management planning process, we actually did put together a comprehensive global pandemic plan. And again, we'll know that when it happens. Hello. Our base business is strong, and we have a talented and dedicated global team that positions us very well for this challenge. Our next question comes from Larry Biegelsen with Wells Fargo. View original content to download multimedia:http://www.prnewswire.com/news-releases/zimmer-biomet-announces-webcast-and-conference-call-of-third-quarter-2020-financial-results-301146445.html, Kontakt  -  And as a result of that, to the extent possible, we were as ready for COVID-19 as you can be.